The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med1995; 333: 1581–1587.
2.
HackeWKasteMBluhmkiEet al.Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med2008; 359: 1317–1329.
3.
IST-3 Collaborative Group,SandercockPWardlawJMet al.The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet2012; 379: 2352–2363.
4.
EmbersonJLeesKRLydenPet al.Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet2014; 384: 1929–1935.
5.
WardlawJMMurrayVBergeEet al.Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet2012; 379: 2364–2372.
6.
SaverJLGoyalMvan der LugtAet al.Time to treatment With endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA2016; 316: 1279–1288.
7.
GoyalMDemchukAMMenonBKet al.Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med2015; 372: 1019–1030.
8.
NogueiraRGJadhavAPHaussenDCet al.Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med2018; 378: 11–21.
9.
AlbersGWMarksMPKempSet al.Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med2018; 378: 708–718.
10.
HillMDKenneyCDzialowskiIet al.Tissue Window in Stroke Thrombolysis study (TWIST): a safety study. Can J Neurol Sci2013; 40: 17–20.
11.
BalSBhatiaRShobhaNet al.Stroke-on-awakening: safety of CT-CTA based selection for reperfusion therapy. Can J Neurol Sci2014; 41: 182–186.
12.
HillMDGoyalMDemchukAMFisherM. Ischemic stroke tissue-window in the new era of endovascular treatment. Stroke2015; 46: 2332–2334.
13.
GoyalMMenonBKAlmekhlafiMADemchukAHillMD. The need for better data on patients with acute stroke who are not treated because of unfavorable imaging. AJNR Am J Neuroradiol2017; 38: 424–425.
14.
HolodinskyJKWilliamsonTSKamalNMayankDHillMDGoyalM. Drip and ship versus direct to comprehensive stroke center: conditional probability modeling. Stroke2017; 48: 233–238.
15.
MilneMSHolodinskyJKHillMDet al.Drip ‘n ship versus mothership for endovascular treatment: modeling the best transportation options for optimal outcomes. Stroke2017; 48: 791–794.
